Alexander Thompson

Jiale Song

Thomas Smith

Corinne Jenkins

Gavin Clark-Gartner

- Aclaris Therapeutics, a clinical-stage biopharmaceutical company, expects multiple data readouts and catalysts in **2026** across its four key assets.  **[1557746_tx_379969_0]** 
- Key pipeline milestones include top-line data for its TSLP monoclonal antibody (ATI-405) in atopic dermatitis in **2026**, and bispecific (ATI-502) SADMAD data by the **end of 2025**, with two Phase Ib readouts in **2026**.  **[1557746_tx_379969_0]** 
- The company's oral ITK/JAK3 small molecule inhibitor (2138) will move into **alopecia areata later in 2025** following strong atopic dermatitis data.  **[1557746_tx_379969_0]** 
- Aclaris reported a cash balance of approximately **$181 million**, providing a cash runway through **mid-year 2028**, and is exploring monetizing its **IP royalty with Sun Pharma** in **2025** for non-dilutive financing.  **[1557746_tx_379969_7]**

Aclaris Therapeutics (ACRS)